💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of formulations and active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, stagnant business, priced for perfection — but flagged on governance.
ORCHID PHARMA is scored on the pharma / healthcare framework. It keeps a thin 0.8% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 11.83× reported profit. Free cash flow is worth about -2.9% of its market value.
Over the last 3 years revenue compounded at 23%/yr and profit at -40%/yr. Book value itself has compounded 32%/yr — the hallmark of a genuine compounder. Return on equity is a weak 1.3%. In the latest quarter profit fell 90% versus the prior quarter.
At 496× earnings, the stock sits at the 100th percentile of its own 3.2-year range — the expensive end of where it has historically traded. Today's price already implies ~55%/yr earnings growth sustained for a decade — a demanding bar. The forensic screen raises 2 red flags: 349% of pre-tax profit is other income, not operations; Share count up 31% over 4 years — heavy equity dilution.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 484.61 | — | — |
| P/B | 3.32 | 4.1 | better |
| EV/EBITDA | 89.44 | 19.33 | worse |
| ROE | 1.34 | 0.3 | better |
| ROCE | 1.62 | — | — |
| ROA | 0.62 | 1.64 | worse |
| Quick Ratio | 1.13 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 23% CAGR over 3 years — high-growth territory. Growth is accelerating — latest year outpaced the prior year's rate.
Profit is on a 2-year growth streak. Revenue is outpacing profit (23% vs -40%) — costs are rising faster than the top line. The latest year saw a -89% swing — check if it's a one-off or structural.
Operating margin has compressed from 8% to 1% — costs or competition are eating into profitability.
ROE at 1% — modest; the capital isn't working hard. Capital efficiency declining — ROE down 7pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. Profit grew faster than EPS (-40% vs -47%) — share dilution is eroding per-share value. -47% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 11.8× PAT — earnings are well-backed by cash; strong accrual quality. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 19% QoQ — could be seasonality or a genuine slowdown. Wide quarterly swings (46% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate stepping up — recent quarters average 64% above earlier ones.
2 of 4 quarters loss-making — quarterly profitability is uneven. Profit fell 90% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly net margins are expanding (-2% → 1%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.2y median.
Promoters hold 74.5% — heavily owner-operated with strong skin in the game. Promoters added 4.6pp over 4 quarters — creeping acquisition signals conviction. MF stake down 2.6pp — domestic funds are booking profits or rebalancing out.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.